[go: up one dir, main page]

LT4039675T - Fenil-2-hidroksi-acetilamino-2-metil-fenilo junginiai - Google Patents

Fenil-2-hidroksi-acetilamino-2-metil-fenilo junginiai

Info

Publication number
LT4039675T
LT4039675T LTEP21211015.9T LT21211015T LT4039675T LT 4039675 T LT4039675 T LT 4039675T LT 21211015 T LT21211015 T LT 21211015T LT 4039675 T LT4039675 T LT 4039675T
Authority
LT
Lithuania
Prior art keywords
phenyl
acetylamino
hydroxy
methyl
compounds
Prior art date
Application number
LTEP21211015.9T
Other languages
English (en)
Inventor
Marta Maria CIFUENTES-GARCIA
Maria Cristina GARCIA-PAREDES
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of LT4039675T publication Critical patent/LT4039675T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
LTEP21211015.9T 2017-04-18 2018-04-11 Fenil-2-hidroksi-acetilamino-2-metil-fenilo junginiai LT4039675T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17382207 2017-04-18

Publications (1)

Publication Number Publication Date
LT4039675T true LT4039675T (lt) 2024-10-10

Family

ID=58606227

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP21211015.9T LT4039675T (lt) 2017-04-18 2018-04-11 Fenil-2-hidroksi-acetilamino-2-metil-fenilo junginiai
LTEPPCT/US2018/027005T LT3612519T (lt) 2017-04-18 2018-04-11 Fenil-2-hidroksi-acetilamino-2-metil-fenilo junginiai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/027005T LT3612519T (lt) 2017-04-18 2018-04-11 Fenil-2-hidroksi-acetilamino-2-metil-fenilo junginiai

Country Status (30)

Country Link
US (2) US11655214B2 (lt)
EP (2) EP3612519B1 (lt)
JP (2) JP7110232B2 (lt)
KR (2) KR102575246B1 (lt)
CN (2) CN110831927B (lt)
AU (2) AU2018255191B2 (lt)
BR (1) BR112019021867A2 (lt)
CO (1) CO2019012767A2 (lt)
CR (1) CR20190519A (lt)
CY (1) CY1125150T1 (lt)
DK (2) DK4039675T3 (lt)
ES (2) ES2906847T3 (lt)
FI (1) FI4039675T3 (lt)
HR (2) HRP20220263T1 (lt)
HU (2) HUE057745T2 (lt)
IL (2) IL270005B (lt)
LT (2) LT4039675T (lt)
MX (2) MX389724B (lt)
MY (1) MY199442A (lt)
NZ (1) NZ758291A (lt)
PH (1) PH12019502363B1 (lt)
PL (2) PL3612519T3 (lt)
PT (2) PT4039675T (lt)
RS (2) RS62933B1 (lt)
SA (1) SA519410320B1 (lt)
SG (1) SG11201909680UA (lt)
SI (2) SI3612519T1 (lt)
SM (2) SMT202400357T1 (lt)
WO (1) WO2018194885A1 (lt)
ZA (1) ZA201906811B (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909680UA (en) * 2017-04-18 2019-11-28 Lilly Co Eli Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
WO2019191115A1 (en) 2018-03-26 2019-10-03 Icahn School Of Medicine At Mount Sinai Methods of treating minimal residual cancer
KR20220068224A (ko) * 2019-08-29 2022-05-25 히버셀, 인크. Perk 억제 화합물
WO2021041976A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting indolinyl compounds
WO2021041970A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting imidazolopyrazine compounds
MX2022002446A (es) * 2019-08-29 2022-06-02 Hibercell Inc Compuestos de pirrolopirimidina inhibidores de perk.
WO2021231782A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibitors for treating viral infections
WO2021231788A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds to treat viral infections
CN113234029B (zh) * 2021-05-25 2022-03-22 白银康寓信生物科技有限公司 一种2-氨基-3,5-二卤代吡嗪的合成方法
AU2024242199A1 (en) * 2023-03-30 2025-10-30 Hibercell, Inc. Crystalline forms of (r)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)-n-isopropylnicotinamide and methods for using the same
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001516353A (ja) 1997-03-19 2001-09-25 ビーエーエスエフ アクチェンゲゼルシャフト ピロロ［２，３ｄ］ピリミジンおよびチロシンキナーゼ阻害剤としてのこれらの使用
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
CA2484209C (en) 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
CA2620818A1 (en) * 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
EP2618146B1 (en) 2008-02-25 2015-06-17 Nestec S.A. Drug selection for breast cancer therapy using antibody-based arrays
US20120014911A1 (en) 2009-01-09 2012-01-19 Serge Fuchs Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
EP2986286A1 (en) 2013-04-15 2016-02-24 Universita' Degli Studi di Bari Galloyl benzamide-based compounds as jnk modulators
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
ES2685661T3 (es) 2013-11-08 2018-10-10 Ono Pharmaceutical Co., Ltd. Derivado de pirrolopirimidina
JP2017507967A (ja) 2014-03-11 2017-03-23 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｐｅｒｋ阻害剤として作用する化合物
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
CA2967125C (en) 2014-11-14 2022-10-25 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
AU2016297754A1 (en) * 2015-07-24 2018-02-15 Blueprint Medicines Corporation Compounds useful for treating disorders related to KIT and PDGFR
CN109153680B (zh) 2016-07-07 2021-04-23 株式会社大熊制药 4-氨基吡唑并[3,4-d]嘧啶基氮杂双环衍生物及含其的药物组合物
AU2017300123A1 (en) 2016-07-20 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as PERK inhibitors
CN106748989B (zh) 2016-11-14 2020-03-17 西安交通大学 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用
WO2018138358A1 (en) 2017-01-30 2018-08-02 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
SG11201909680UA (en) 2017-04-18 2019-11-28 Lilly Co Eli Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
JP7304855B2 (ja) 2017-11-14 2023-07-07 ザ チルドレンズ メディカル センター コーポレーション 新規イミダゾピリミジン化合物およびそれらの使用
EP3492454A1 (en) 2017-11-30 2019-06-05 Step Pharma S.A.S. Compounds
WO2019191115A1 (en) 2018-03-26 2019-10-03 Icahn School Of Medicine At Mount Sinai Methods of treating minimal residual cancer
CN112384283B (zh) 2018-07-06 2023-08-15 吉利德科学公司 治疗性的杂环化合物
US20220040183A1 (en) 2018-10-01 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of stress granule formation for targeting the regulation of immune responses

Also Published As

Publication number Publication date
DK3612519T3 (da) 2022-03-07
JP2022141835A (ja) 2022-09-29
RS65914B1 (sr) 2024-10-31
CR20190519A (es) 2020-03-06
AU2018255191A1 (en) 2019-11-07
CY1125150T1 (el) 2023-06-09
AU2018255191B2 (en) 2022-04-21
PL3612519T3 (pl) 2022-05-02
AU2022206702A1 (en) 2022-08-11
PH12019502363A1 (en) 2020-12-07
US11655214B2 (en) 2023-05-23
KR102575246B1 (ko) 2023-09-06
IL270005B (en) 2022-01-01
ES2988739T3 (es) 2024-11-21
SA519410320B1 (ar) 2022-05-08
IL288822A (en) 2022-02-01
EP4039675A1 (en) 2022-08-10
SMT202400357T1 (it) 2024-11-15
PT3612519T (pt) 2022-02-22
RS62933B1 (sr) 2022-03-31
KR20230129627A (ko) 2023-09-08
HRP20220263T1 (hr) 2022-04-29
ZA201906811B (en) 2021-01-27
JP7110232B2 (ja) 2022-08-01
SI4039675T1 (sl) 2024-10-30
SI3612519T1 (sl) 2022-04-29
CO2019012767A2 (es) 2020-04-01
RU2019136694A3 (lt) 2021-05-19
CN117510405A (zh) 2024-02-06
NZ758291A (en) 2025-11-28
IL288822B2 (en) 2023-06-01
PL4039675T3 (pl) 2025-01-07
EP4039675B1 (en) 2024-06-12
BR112019021867A2 (pt) 2020-05-26
HUE057745T2 (hu) 2022-06-28
LT3612519T (lt) 2022-03-25
FI4039675T3 (fi) 2024-09-10
RU2019136694A (ru) 2021-05-18
CN110831927B (zh) 2023-07-14
DK4039675T3 (da) 2024-09-02
HRP20241188T1 (hr) 2024-12-06
HUE068023T2 (hu) 2024-12-28
SG11201909680UA (en) 2019-11-28
EP3612519B1 (en) 2021-12-01
ES2906847T3 (es) 2022-04-20
MX2019012428A (es) 2022-01-28
SMT202200100T1 (it) 2022-03-21
KR20190140966A (ko) 2019-12-20
JP2021517555A (ja) 2021-07-26
CA3060564A1 (en) 2018-10-25
JP7331212B2 (ja) 2023-08-22
MX389724B (es) 2025-03-20
AU2022206702B2 (en) 2024-04-11
EP3612519A1 (en) 2020-02-26
PH12019502363B1 (en) 2023-11-15
US20230373922A1 (en) 2023-11-23
MX2022001310A (es) 2022-03-02
US20210114985A1 (en) 2021-04-22
MY199442A (en) 2023-10-28
PT4039675T (pt) 2024-09-16
CN110831927A (zh) 2020-02-21
WO2018194885A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
GB201708456D0 (en) Senolytic compounds
GB201704327D0 (en) Compounds
GB201715342D0 (en) Compounds
PT3612519T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
GB201704325D0 (en) Compounds
GB201716871D0 (en) Compounds
GB201713962D0 (en) Compounds
GB201717051D0 (en) Compounds
GB201707938D0 (en) Compounds
GB201707856D0 (en) Compounds
GB201706162D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201715786D0 (en) Compounds
GB201720064D0 (en) Compounds
GB201716392D0 (en) Compounds
GB201707852D0 (en) Compounds
GB201703282D0 (en) Compounds
GB201721330D0 (en) Compounds
GB201721331D0 (en) Compounds
GB201721326D0 (en) Compounds
GB201720495D0 (en) ß-lactone compounds
GB201719261D0 (en) Compounds
GB201717718D0 (en) Compounds
GB201717050D0 (en) Compounds